A new drug for the treatment of migraine may appear in Europe
The Expert Council of the European Medicines Agency recommended that regulatory authorities approve the preparation of galcanesumab, developed by the American company Eli Lilly for the treatment of a migraine.
Clinical studies show that the drug is effective in reducing the number of attacks of a headache. Galceanumab is a monoclonal antibody specific for the CGRP protein, which plays an important role in the development of a migraine and cluster headache. The injection drug is intended for self-administration by the patient at a frequency of once a month.
In addition to Eli Lilly, Amgen, Teva and Allergan are involved in the development of CGRP-specific drugs. So, last week Teva received a positive decision from the US FDA for its drug for the treatment of a migraine. The decision of US regulators on galcezumab will be announced at the end of this month.